Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Blueprint Medicines price target raised to $119 from $109 at Piper Sandler
Piper Sandler raised the firm’s price target on Blueprint Medicines (BPMC) to $119 from $109 and keeps an Overweight rating on the shares ahead ...
Gentherm price target lowered to $51 from $56 at JPMorgan
JPMorgan lowered the firm’s price target on Gentherm (THRM) to $51 from $56 and keeps a Neutral rating on the shares as part of a Q4 preview ...